阿坎托西德B通过抑制TAGE/RAGE通路来减轻NLRP3介导的烧亡和性结肠炎
Xiaobo He1, Chunfang Zhou1, Rui Shang1
1Department of Gastroenterology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei Province, China.
Allergologia et immunopathologia
|January 9, 2025
概括
阿坎托西德B (Aca.B) 通过减少炎症和热致死,有效治疗性结肠炎. 这种化合物抑制了AGE/RAGE通路,为新型抗炎疗法提供了潜力.
科学领域:
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
背景情况:
- 性结肠炎 (UC) 是一种炎症性肠病,原因不明.
- 来自Pogostemon cablin的Acanthoside B (Aca.B) 显示出抗炎性质,但其UC治疗潜力尚未被探索.
研究的目的:
- 在体外和体内研究Aca.B对性结肠炎 (UC) 的治疗效果.
- 阐明底层机制,重点关注热和AGE/RAGE通路.
主要方法:
- 在体外:用LPS刺激的MODE-K细胞来评估Aca.B对细胞活力和炎症的影响.
- 在体内:小鼠中硫酸 (DSS) 诱导的大肠炎模型,以评估Aca.B对疾病进展,热和AGE/RAGE信号的影响.
主要成果:
- Aca.B显著改善了细胞活力,并减少了LPS治疗细胞中的炎症.
- 在DSS诱导的大肠炎小鼠中,Aca.B治疗减弱了 pyroptosis 标记物,炎症性细胞因子,并改善了症状.
- Aca.B抑制了AGE/RAGE通路,减少了AGE的积累和下游的炎症信号.
结论:
- 在性结肠炎模型中,阿坎托西德B显示出显著的抗炎和抗火作用.
- Aca.B 的治疗作用包括抑制 AGE/RAGE 信号通路.
- Aca.B显示为潜在的临床治疗性结肠炎的潜在临床治疗剂.
相关概念视频
T Cell Types and Functions
946
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
946
NF-κB-dependent Signaling Pathway
7.2K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.2K
Drugs for Treatment of Ulcerative Colitis in IBD
119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119
The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
The Extrinsic Apoptotic Pathway
6.2K
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.2K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
114
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
114


